Chengyu Wang
Researcher in Child and Adolescent Psychiatry at the Affiliated Brain Hospital of Guangzhou Medical University
Data updated
Papers
Trials
Research Footprint
Chengyu Wang appears in 13 tracked papers (2018–2024), most studied alongside Ketamine, Esketamine and Placebo, across Depressive Disorders, Major Depressive Disorder (MDD) and Suicidality.
Most-cited paper: Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression (179 citations).
Frequent co-authors: Yanling Zhou, Yuping Ning and Wei Zheng.
Background & Research
Chengyu Wang appears to be a clinician-researcher based at the Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital) in Guangzhou, China. Across several studies, he has coauthored work on repeated intravenous ketamine and esketamine for major depressive disorder, suicidal ideation, cognition, and functional brain connectivity. The papers place him within a research group focused on biological and clinical mechanisms of rapid-acting antidepressant treatments.
Key Impact
He is a coauthor on multiple clinical ketamine and esketamine studies examining antidepressant, antisuicidal, cognitive, and neuroimaging effects in depression and suicidality.
Collaboration Network
7 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Chengyu Wang is associated with.